Syncromune to Present Updated Prostate Cancer Survival Data at ESMO Congress

Syncromune, Inc., a privately held clinical-stage biopharmaceutical company based in Fort Lauderdale, Florida, and West Des Moines, Iowa, announced that updated long-term overall survival (OS) data from a Phase 1 trial of its SYNC-T Therapy SV-102 in patients with metastatic prostate cancer will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place from October 23 to 27, 2026, in Madrid, Spain.

The session is categorized under the category of metastatic prostate cancer and will take place on Friday, October 23, 2026, from 15:15 to 16:10 CEST.

Syncromune continues to advance the ongoing, multicenter, Phase 2a LEGION-100 trial (NCT06533644), which is evaluating SYNC-T Therapy SV-102 in patients with metastatic castration-resistant prostate cancer (mCRPC). The company is committed to developing SYNC-T, a potentially first-in-class platform immunotherapy designed to address major unmet medical needs and treatment challenges in metastatic solid tumor cancers.

The SYNC-T Therapy SV-102 platform features a novel proprietary needle-based device delivery system designed for combination drug/device immunotherapy. The system first lyses a portion of the target tumor via a proprietary freeze/thaw method to release patient-specific tumor antigens into the tumor microenvironment (TME), with the goal of activating the immune system. Next, the delivery system facilitates the infusion of the investigational multi-target immunomodulatory drug directly into the lysed area of the tumor, promoting the flow of antigens and the drug into tumor-draining lymph nodes. This co-localization approach is designed to unite three components involved in T cell activation, with the goal of promoting in situ immune activation, addressing immune suppression, and limiting systemic drug exposure.

Syncromune's announcement comes as the company seeks to advance its pipeline and clinical infrastructure, with the goal of generating a systemic anti-tumor response that may recognize and attack both primary and metastatic tumors throughout the body and support immune memory. The company's efforts are in line with its mission to develop innovative immunotherapies that address unmet medical needs in metastatic solid tumor cancers.